Tiziana Life files new patent application related to GLP-1ra, foralumab

Tiziana Life Sciences (TLSA) announced filing of a new patent application relating to composition and methods for combining GLP-1ra and foralumab, a fully human anti-CD3 antibody, to achieve further reductions in systemic and vascular inflammation associated with Type 2 Diabetes and also in a separate population of patients with non T2D obesity. Effectiveness of GLP-1ra non T2D obesity was recently shown in the greater than17,600 patient SELECT trial by Novo Nordisk (NVO). SELECT showed a 20% reduction of major adverse cardiovascular events such as heart attack, stroke, and peripheral vascular disease, with semaglutide. Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences said, “I believe that our commitment to improving patient outcomes by using anti-CD3, or foralumab, in risk mitigation for MACE could be another exciting indication for foralumab. We hope our efforts will give a new therapeutic option to patients afflicted with Type 2 Diabetes and non T2D obesity that are receiving GLP-1 receptor antagonists. We believe the risk reduction could be substantial with combination therapy.”